By creating this super innovation centre "outside the walls", which is Marseille Immunopole, we leverage our capabilities to ensure better and faster innovation.

A therapeutic revolution is happening.

The Explore covid-19 project was born from combining the forces of Marseille Immunopôle. It should lead us to better understand this new disease and improve the prognosis of our patients.

Today Marseille Immunopôle is a great opportunity to challenge our discipline with novel perspectives.

The Pioneer Project is unique as a strong public/private partnership between academia, a medical cancer center, 3 biotechs and a major pharma

Education is also one of the strategic components of the Marseille Immunopole project.

Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.

Each year, a large number of clinical trials are conducted by APHM clinicians alone or in partnership with industry players in biopharmaceuticals.

Being primarily centred on the patient, my work combines the short-term management of the disease and the long-term of clinical research.

MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.

“Projects like PIONeeR allow us to contribute to the understanding of resistance to immunotherapy while opening clinical research to patients in Corsica, who, until recently, had no choice other than to fly to Marseille or Paris for such opportunities.”

Our study models help to identify new potential therapeutic targets in preclinical models of personalized medicine.

Today, the Covid-19 pandemic serves as an eye-opener, once again demonstrating the strength of the Marseille Immunopôle collective

Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.